Search Results

Aptose Biosciences Inc. announced the voting results from the Company’s annual and special meeting of shareholders held today, June 18, 2024.

Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced financial results for the first quarter ended March 31, 2024.

Aptose Biosciences Inc. announced a clinical poster presentation and a preclinical e-poster at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain.

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the three months and year ended December 31, 2023, and provided a corporate update.